Edwards Unveils Data Challenging Moderate Aortic Stenosis Treatment Guidelines
Event summary
- Edwards presented PROGRESS trial baseline data at New York Valves 2026 showing 95% of moderate aortic stenosis patients were symptomatic and 73% had multiple risk factors.
- Seven-year durability data for SAPIEN 3 platform published in JAMA Cardiology reinforces long-term performance claims.
- Real-world data from 4,500 PASCAL system patients demonstrates sustained safety and effectiveness for mitral regurgitation treatment.
- SAPIEN M3 showed quality of life improvements in ENCIRCLE trial for patients with mitral annular calcification.
The big picture
Edwards' data presentations challenge current treatment paradigms for aortic stenosis, potentially expanding the addressable patient population. The focus on long-term durability and real-world evidence aligns with broader industry shifts toward value-based healthcare delivery. With structural heart disease treatments becoming more proactive rather than reactive, Edwards positions itself as a leader in defining new clinical standards.
What we're watching
- Guideline Evolution
- Whether PROGRESS trial data will accelerate TAVR adoption for moderate aortic stenosis patients before current guideline recommendations.
- Competitive Differentiation
- How Edwards' long-term durability claims for SAPIEN platform will position it against emerging transcatheter valve technologies.
- Regulatory Pathways
- The pace at which real-world evidence from PASCAL system and SAPIEN M3 will support expanded indications or reimbursement approvals.